The Use of Metyrosine in the Treatment of Pheochromocytoma and Paraganglioma Patients: A Review of the Literature

Metyrosine (α-methyl-parathyrosine) functions as an inhibitor of tyrosine hydroxylase, thereby impeding the conversion of tyrosine to 3,4-dihydroxyphenylalanine. This reaction represents the rate-limiting step in the synthesis of catecholamines. This review examines the mechanisms of metyrosine acti...

Full description

Bibliographic Details
Published in:	Archives of Basic and Clinical Research
Main Authors:	Mansura Babayeva, Osman Kağan Çakır, Gülbaniz Hüseynova, Halis Süleyman
Format:	Article
Language:	English
Published:	Erzincan Binali Yıldırım University School of Medicine 2025-05-01
Subjects:	metyrosine pheochromocytoma paraganglioma
Online Access:	https://abcresearch.net/articles/the-use-of-metyrosine-in-the-treatment-of-pheochromocytoma-and-paraganglioma-patients-a-review-of-the-literature/doi/ABCR.2025.24317

Similar Items

Review of Pediatric Pheochromocytoma and Paraganglioma
by: Reshma Bholah, et al.
Published: (2017-07-01)

Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma
by: Yuko Matsuo, et al.
Published: (2023-10-01)

Pheochromocytomas/Paragangliomas and two cases
by: W. van Vuuren, et al.
Published: (2007-06-01)

Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
by: Eu Jeong Ku, et al.
Published: (2021-04-01)

Immune microenvironment of pheochromocytomas and paragangliomas
by: ZHOU Yue, TONG Anli
Published: (2024-06-01)

The Pheochromocytoma/Paraganglioma syndrome: an overview on mechanisms, diagnosis and management
by: José Viana Lima Junior, et al.
Published: (2023-06-01)

Surgical strategies of complicated pheochromocytomas/paragangliomas and literature review
by: Xu Wang, et al.
Published: (2023-04-01)

The effects of metyrosine on ischemia-reperfusion-induced oxidative ovarian injury in rats: Biochemical and histopathological assessment
by: OMER E. YAPCA, et al.
Published: (2023-04-01)

Update on Modern Management of Pheochromocytoma and Paraganglioma
by: Jacques W. M. Lenders, et al.
Published: (2017-06-01)

Characteristics of pediatric pheochromocytoma/paraganglioma
by: Vijaya Sarathi
Published: (2017-01-01)

External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
by: Jennifer eVogel, et al.
Published: (2014-06-01)

Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas
by: Anastasiya Snezhkina, et al.
Published: (2021-11-01)

Misdiagnosis and analysis of clinical characteristics in patients with giant cystic pheochromocytoma/paraganglioma
by: Yue Zhang, et al.
Published: (2024-12-01)

An uncommon cause of hypertension: Paraganglioma revisited
by: Babulreddy Hanmayyagari, et al.
Published: (2015-01-01)

Clinical profiles of patients with surgically resected pheochromocytoma and paraganglioma
by: Sun Hwa Lee, et al.
Published: (2020-03-01)

Factors contributing to development and resolution of dysglycemia in patients with pheochromocytomas and catecholamine-secreting paragangliomas
by: Lin Zhao, et al.
Published: (2023-12-01)

Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report
by: Masahiro Shibata, et al.
Published: (2017-12-01)

Hereditary and clinical insights into paraganglioma and pheochromocytoma
by: Caitlin B Mauer Hall, et al.
Published: (2024-11-01)

Cancer Stem Cells in Pheochromocytoma and Paraganglioma
by: Laura D. Scriba, et al.
Published: (2020-02-01)

Editorial: Predictive tools in pheochromocytoma and paraganglioma
by: Filippo Ceccato, et al.
Published: (2023-06-01)

Pheochromocytoma/paraganglioma-associated cardiomyopathy
by: Alicja Szatko, et al.
Published: (2023-07-01)

Hemodynamic parameters in patients undergoing surgery for pheochromocytoma/paraganglioma: a retrospective study
by: Giuseppina De Filpo, et al.
Published: (2023-06-01)

Research in Robot-assisted Surgery for Pheochromocytoma and Paraganglioma
by: OU Minjie, et al.
Published: (2024-07-01)

Whole transcriptome analysis of canine pheochromocytoma and paraganglioma
by: Marit F. van den Berg, et al.
Published: (2023-08-01)

DNA methylation analysis in malignant pheochromocytoma and paraganglioma
by: Toshihiro Oishi, et al.
Published: (2017-03-01)

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT
by: Erica S. Tsang, et al.
Published: (2021-07-01)

The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update
by: Bruno Bouça, et al.
Published: (2022-02-01)

Sex differences in presentation of pheochromocytoma and paraganglioma
by: Nora Azin Ali, et al.
Published: (2025-01-01)

Association of NSE level with clinical features in pheochromocytoma/paraganglioma
by: LI Tianyi, ZHANG Wenqian, CHEN Yinghan, ZHOU Yue, CUI Yunying, WANG Yu, TONG Anli
Published: (2024-04-01)

Clinical differences between small and large pheochromocytomas and paragangliomas
by: Lin Zhao, et al.
Published: (2023-03-01)

Efficacy of Immunohistochemistry for SDHB in the Screening of Hereditary Pheochromocytoma–Paraganglioma
by: Hye-Ryeon Choi, et al.
Published: (2021-07-01)

Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma
by: Graeme Eisenhofer, et al.
Published: (2022-07-01)

Novel and recurrent genetic variants of VHL, SDHB, and RET genes in Chinese pheochromocytoma and paraganglioma patients
by: Chong Li, et al.
Published: (2023-03-01)

Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
by: Camilo Jimenez
Published: (2018-05-01)

Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis
by: Dan Su, et al.
Published: (2023-07-01)

Hot Trends in Pheochromocytoma and Paraganglioma: Are We Getting Closer to Personalized Dynamic Prognostication?
by: C. Christofer JUHLIN, et al.
Published: (2024-09-01)

The Biochemical–Imaging Connection: Urinary Noradrenaline and Fluorodeoxyglucose-Positron Emission Tomography in Unresectable or Metastatic Pheochromocytomas and Paragangliomas
by: Junki Takenaka, et al.
Published: (2025-05-01)

Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension
by: Letizia Canu, et al.
Published: (2019-06-01)

Tumour microenvironment in pheochromocytoma and paraganglioma
by: Serena Martinelli, et al.
Published: (2023-03-01)

Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy
by: Richard A. Erali, et al.
Published: (2025-10-01)